Known targets — ChEMBL curated mechanism
HDAC1HDAC10HDAC11HDAC2HDAC3HDAC4HDAC5HDAC6HDAC7HDAC8HDAC9
The experimentally established mechanism targets of Abexinostat. The predicted profile below is derived independently by chemical similarity — agreement is a validation signal, a miss is honest.
Predicted protein targets (top 20)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | HDAC6 known ✓ | Q9UBN7 | 4/20 | 1.00 |
| ▸ | HDAC1 known ✓ | Q13547 | 3/20 | 1.00 |
| ▸ | HDAC3 known ✓ | O15379 | 2/20 | 1.00 |
| ▸ | HDAC2 known ✓ | Q92769 | 2/20 | 1.00 |
| ▸ | HDAC10 known ✓ | Q969S8 | 2/20 | 1.00 |
| ▸ | HDAC8 known ✓ | Q9BY41 | 2/20 | 1.00 |
| ▸ | HDAC4 known ✓ | P56524 | 1/20 | 1.00 |
| ▸ | HDAC7 known ✓ | Q8WUI4 | 1/20 | 1.00 |
| ▸ | HDAC11 known ✓ | Q96DB2 | 1/20 | 1.00 |
| ▸ | HDAC9 known ✓ | Q9UKV0 | 1/20 | 1.00 |
| ▸ | HDAC5 known ✓ | Q9UQL6 | 1/20 | 1.00 |
| ▸ | NCOR2 | Q9Y618 | 1/20 | 1.00 |
| ▸ | LMNA | P02545 | 5/20 | 0.50 |
| ▸ | L3MBTL1 | Q9Y468 | 4/20 | 0.50 |
| ▸ | HTT | P42858 | 2/20 | 0.50 |
| ▸ | MAPT | P10636 | 2/20 | 0.50 |
| ▸ | KDM4E | B2RXH2 | 1/20 | 0.50 |
| ▸ | TDP1 | Q9NUW8 | 1/20 | 0.50 |
| ▸ | GAA | P10253 | 1/20 | 0.50 |
| ▸ | RXFP1 | Q9HBX9 | 2/20 | 0.45 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| Abexinostat SCHEMBL29489677 | 1.00 | HDAC6 (1.00) | HDAC6HDAC1HDAC3HDAC2HDAC10 | |
| Abexinostat SCHEMBL14762281 | 0.99 | HDAC6 (1.00) | HDAC6HDAC1HDAC3HDAC2HDAC10 | |
| Abexinostat SCHEMBL29544306 | 0.99 | HDAC6 (1.00) | HDAC6HDAC1HDAC3HDAC2HDAC10 | |
| SCHEMBL4252161 | 0.92 | HDAC1 (0.84) | HDAC6HDAC1HDAC3HDAC2HDAC10 | |
| SCHEMBL14769055 | 0.92 | HDAC1 (0.84) | HDAC6HDAC1HDAC3HDAC2HDAC10 | |
| SCHEMBL13029066 | 0.91 | HDAC3 (0.84) | HDAC6HDAC1HDAC3HDAC2HDAC10 | |
| Abexinostat SCHEMBL29454805 | 0.90 | HDAC6 (0.82) | HDAC6HDAC1HDAC3HDAC2HDAC10 | |
| SCHEMBL445592 | 0.90 | HDAC8 (0.82) | HDAC6HDAC1HDAC3HDAC2HDAC10 | |
| SCHEMBL13029067 | 0.90 | HDAC3 (0.82) | HDAC6HDAC1HDAC3HDAC2HDAC10 | |
| Potassium Ion SCHEMBL443346 | 0.90 | HDAC3 (0.82) | HDAC6HDAC1HDAC3HDAC2HDAC10 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Appears in 2526 patents — a generic fragment claimed broadly, so it's down-weighted as IP noise. Top by claim status then date:
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| WO-2026107052-A1 | COMBINATION TREATMENTS USING EPIGENETIC INHIBITION AND SYNGRI-MEDIATED FRATAXIN EXPRESSION | ST. JUDE CHILDREN'S RESEARCH HOSPITAL, INC. (US) | 2026-05-21 | — | — | WO | claimed |
| US-12630624-B2 | Anti-IL-27 antibodies and uses thereof | Surface Oncology, LLC (US) | 2026-05-19 | — | — | US | claimed |
| US-20260125650-A1 | METHODS AND COMPOSITIONS FOR GENERATING HEPATOCYTES | TRAILHEAD BIOSYSTEMS INC (US) | 2026-05-07 | — | — | US | claimed |
| US-20260108619-A1 | CONJUGATION LINKERS, CELL BINDING MOLECULE-DRUG CONJUGATES CONTAINING THE LINKERS, METHODS OF MAKING AND USES SUCH CONJUGATES WITH THE LINKERS | HANGZHOU DAC BIOTECH CO., LTD. (CN) | 2026-04-23 | — | — | US | claimed |
| EP-4728051-A1 | STANDARDISING PLURIPOTENT STEM CELLS | United Kingdom Research and Innovation (GB) | 2026-04-22 | — | — | EP | claimed |
| US-12599662-B2 | Methods and compositions for treating cancers | INSERM (Institut National de la Santé et de la Recherche Médicale) (FR) | 2026-04-14 | — | — | US | claimed |
| EP-4720316-A2 | NON-VIRAL CELL ENGINEERING | Arsenal Biosciences, Inc. (US) | 2026-04-08 | — | — | EP | claimed |
| US-12582635-B2 | Compositions and methods for treating cancer with atypical BRAF mutations | BIOMED VALLEY DISCOVERIES, INC. (US) | 2026-03-24 | — | — | US | claimed |
| US-12576124-B2 | Formulation of a conjugate of a tubulysin analog to a cell-binding molecule | HANGZHOU DAC BIOTECH CO., LTD (CN) | 2026-03-17 | — | — | US | claimed |
| EP-4676454-A1 | COMBINATION OF ROGINOLISIB AND HDAC INHIBITOR IN THE TREATMENT OF HAEMATOLOGICAL MALIGNANCY | iOnctura SA (CH) | 2026-01-14 | — | — | EP | claimed |
| WO-2013039488-A1 | FORMULATIONS OF HISTONE DEACETYLASE INHIBITOR IN COMBINATION WITH BENDAMUSTINE AND USES THEREOF | PHARMACYCLICS, INC. (US) | 2013-03-21 | — | — | WO | claimed |
| US-20130064880-A1 | ADMINISTRATION REGIME FOR N-HYDROXY-4-BENZAMIDE | PHARMACYCLICS, INC. | 2013-03-14 | — | — | US | claimed |
| EP-2544673-A1 | THIOXANTHONE-BASED AUTOPHAGY INHIBITOR THERAPIES TO TREAT CANCER | Spectrum Pharmaceuticals, Inc. (US) | 2013-01-16 | — | — | EP | claimed |
| US-20110311624-A1 | FORMULATIONS OF HISTONE DEACETYLASE INHIBITOR AND USES THEREOF | PHARMACYCLICS, INC. (US) | 2011-12-22 | — | — | US | claimed |
| US-20110275696-A1 | Thioxanthone-Based Autophagy Inhibitor Therapies to Treat Cancer | SPECTRUM PHARMACEUTICALS, INC. | 2011-11-10 | — | — | US | claimed |
| WO-2011112623-A1 | THIOXANTHONE-BASED AUTOPHAGY INHIBITOR THERAPIES TO TREAT CANCER | SPECTRUM PHARMACEUTICALS, INC. (US) | 2011-09-15 | — | — | WO | claimed |
| US-20110021528-A1 | NOVEL HYDROXAMATES AS THERAPEUTIC AGENTS | PHARMACYCLICS, INC. (US) | 2011-01-27 | — | — | US | claimed |
| EP-1611088-B1 | HYDROXAMATES AS THERAPEUTIC AGENTS | PHARMACYCLICS INC (US) | 2009-06-17 | — | — | EP | claimed |
| US-7276612-B2 | For hepatitis C; histone deacetylase inhibitors; N-hydroxy-4-{[(benzofuran-, benzothiophen-, or indol-)-2-ylcarbonylamino]alkoxy}benzamides | PHARMACYCLICS, INC. (US) | 2007-10-02 | — | — | US | claimed |
| US-20050187261-A1 | For hepatitis C; histone deacetylase inhibitors, anticarcinogenic agents; N-hydroxy-4-{[(benzofuran-, benzothiophen-, or indol-)-2-ylcarbonylamino]alkoxy}benzamides; amidation of a benzoic acid, benzoate, benzoyl halide with hydroxyamine | AXYS PHARMACEUTICALS, INC. (US) | 2005-08-25 | — | — | US | claimed |